Cargando…

Checkpoint inhibitor therapy in preclinical sepsis models: a systematic review and meta-analysis

BACKGROUND: Animal studies reporting immune checkpoint inhibitors (CPIs) improved host defense and survival during bacterial sepsis provided one basis for phase I CPI sepsis trials. We performed a systematic review and meta-analysis examining the benefit of CPI therapy in preclinical studies, and wh...

Descripción completa

Detalles Bibliográficos
Autores principales:	Busch, Lindsay M., Sun, Junfeng, Cui, Xizhong, Eichacker, Peter Q., Torabi-Parizi, Parizad
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2020
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7000606/ https://www.ncbi.nlm.nih.gov/pubmed/32020483 http://dx.doi.org/10.1186/s40635-019-0290-x

Ejemplares similares

Comprehensive adjusted outcome data are needed to assess the impact of immune checkpoint inhibitors in cancer patients with COVID‐19: Results of a systematic review and meta‐analysis
por: Minkove, Samuel J., et al.
Publicado: (2022)

Effect of low-to-moderate hyperoxia on lung injury in preclinical animal models: a systematic review and meta-analysis
por: Minkove, Samuel, et al.
Publicado: (2023)

The Effects of Obesity on Outcome in Preclinical Animal Models of Infection and Sepsis: A Systematic Review and Meta-Analysis
por: Xu, Wanying, et al.
Publicado: (2020)

A systematic review and meta-analysis of preclinical trials testing anti-toxin therapies for B. anthracis infection: A need for more robust study designs and results
por: Xu, Wanying, et al.
Publicado: (2017)

Increased body mass index and adjusted mortality in ICU patients with sepsis or septic shock: a systematic review and meta-analysis
por: Pepper, Dominique J., et al.
Publicado: (2016)

Correction: A systematic review and meta-analysis of preclinical trials testing anti-toxin therapies for B. anthracis infection: A need for more robust study designs and results
por: Xu, Wanying, et al.
Publicado: (2017)

Growing insights into the potential benefits and risks of activated protein C administration in sepsis: a review of preclinical and clinical studies
por: Altaweel, Laith, et al.
Publicado: (2009)

A Review of the Efficacy of FDA-Approved B. anthracis Anti-Toxin Agents When Combined with Antibiotic or Hemodynamic Support in Infection- or Toxin-Challenged Preclinical Models
por: Couse, Zoe, et al.
Publicado: (2021)

Does Bacillus anthracis Lethal Toxin Directly Depress Myocardial Function? A Review of Clinical Cases and Preclinical Studies
por: Suffredini, Dante A., et al.
Publicado: (2015)

The Role of Semaphorins and Their Receptors in Innate Immune Responses and Clinical Diseases of Acute Inflammation
por: Kanth, Shreya M., et al.
Publicado: (2021)

Comparison of survivors and nonsurvivors in 27 confirmed injectional anthrax cases from the 2009 outbreak in Scotland
por: Booth, M, et al.
Publicado: (2013)

Ethical and Practical Considerations in Providing Critical Care to Patients With Ebola Virus Disease
por: Torabi-Parizi, Parizad, et al.
Publicado: (2015)

B. anthracis associated cardiovascular dysfunction and shock: the potential contribution of both non-toxin and toxin components
por: Remy, Kenneth E, et al.
Publicado: (2013)

The Potential Pathogenic Contributions of Endothelial Barrier and Arterial Contractile Dysfunction to Shock Due to B. anthracis Lethal and Edema Toxins
por: Suffredini, Dante A., et al.
Publicado: (2017)

Hydrocortisone decreases lethality and inflammatory cytokine and nitric oxide production in rats challenged with B. anthracis cell wall peptidoglycan
por: Li, Yan, et al.
Publicado: (2020)

Network representations of immune system complexity
por: Subramanian, Naeha, et al.
Publicado: (2015)

Efficacy and safety of immune checkpoint inhibitors for patients with prostate cancer: a systematic review and meta-analysis
por: Noori, Maryam, et al.
Publicado: (2023)

The Potential Contributions of Lethal and Edema Toxins to the Pathogenesis of Anthrax Associated Shock
por: Hicks, Caitlin W., et al.
Publicado: (2011)

Anthrax immune globulin improves hemodynamics and survival during B. anthracis toxin-induced shock in canines receiving titrated fluid and vasopressor support
por: Suffredini, Dante A., et al.
Publicado: (2017)

CNS side effects of immune checkpoint inhibitors: preclinical models, genetics and multimodality therapy
por: McGinnis, Gwendolyn J, et al.
Publicado: (2017)

Efficacy of mesenchymal stem cell therapy for sepsis: a meta-analysis of preclinical studies
por: Sun, Xue-Yi, et al.
Publicado: (2020)

Raxibacumab augments hemodynamic support and improves outcomes during shock with B. anthracis edema toxin alone or together with lethal toxin in canines
por: Remy, Kenneth E, et al.
Publicado: (2015)

Analysis of Anthrax Immune Globulin Intravenous with Antimicrobial Treatment in Injection Drug Users, Scotland, 2009–2010
por: Cui, Xizhong, et al.
Publicado: (2017)

Checkpoint inhibitors in endometrial cancer: preclinical rationale and clinical activity
por: Mittica, Gloria, et al.
Publicado: (2017)

Checkpoint inhibitors in ovarian cancer: A review of preclinical data
por: Doo, David W., et al.
Publicado: (2019)

Confirmed Bacillus anthracis Infection among Persons Who Inject Drugs, Scotland, 2009–2010
por: Booth, Malcolm, et al.
Publicado: (2014)

Immunogenic Chemotherapy Sensitizes Renal Cancer to Immune Checkpoint Blockade Therapy in Preclinical Models
por: Cui, Shujin
Publicado: (2017)

Purified cell wall from the probiotic bacterium Lactobacillus gasseri activates systemic inflammation and, at higher doses, produces lethality in a rat model
por: Xu, Xinhui, et al.
Publicado: (2014)

The gut microbiome and response to immune checkpoint inhibitors: preclinical and clinical strategies
por: Gong, Jun, et al.
Publicado: (2019)

Oncolytic Viruses and Immune Checkpoint Inhibitors: Preclinical Developments to Clinical Trials
por: Hwang, June Kyu, et al.
Publicado: (2020)

Immune Checkpoint Inhibitor Therapy in Neuroendocrine Tumors
por: Gubbi, Sriram, et al.
Publicado: (2022)

Role of Immune Checkpoint Inhibitors in Cervical Cancer: From Preclinical to Clinical Data
por: Duranti, Simona, et al.
Publicado: (2021)

Time Rules the Efficacy of Immune Checkpoint Inhibitors in Photodynamic Therapy
por: Wu, Qinghua, et al.
Publicado: (2022)

Combination of AFP vaccine and immune checkpoint inhibitors slows hepatocellular carcinoma progression in preclinical models
por: Lu, Xinjun, et al.
Publicado: (2023)

Meta‐analysis of immune‐related adverse events of immune checkpoint inhibitor therapy in cancer patients
por: Song, Peng, et al.
Publicado: (2020)

Protective properties of extracellular vesicles in sepsis models: a systematic review and meta-analysis of preclinical studies
por: Yang, Shujun, et al.
Publicado: (2023)

Checkpoint inhibitors for malignant melanoma: a systematic review and meta-analysis
por: Karlsson, Adam K, et al.
Publicado: (2017)

Association of Pulmonary Sepsis and Immune Checkpoint Inhibitors: A Pharmacovigilance Study
por: Xia, Shuang, et al.
Publicado: (2022)

Evolution of preclinical characterization and insights into clinical pharmacology of checkpoint inhibitors approved for cancer immunotherapy
por: Kasichayanula, Sreeneeranj, et al.
Publicado: (2022)

The efficacy and safety of immune checkpoint inhibitor combination therapy in lung cancer: a systematic review and meta-analysis
por: Peng, Min, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_7dpfqvqvp65fsk0noop1tcuj5m